Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: opiates Clear all
Completed Phase 2 Interventional Results available

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

NCT04677114
View directory record Official record
Conditions
Drug Use, Opioid-use Disorder
Interventions
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
Drug
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 4 Interventional Results available

IV Acetaminophen as an Analgesic Adjunct

NCT02621619
View directory record Official record
Conditions
Acute Pain
Interventions
IV acetaminophen + 0.5 mg IV hydromorphone, Normal saline + 0.5 mg IV hydromorphone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
65 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 28, 2026, 6:55 AM EDT
Recruiting Phase 3 Interventional

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

NCT07671911
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Newport Beach, California • Palm Springs, California • Redding, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 6:55 AM EDT
Recruiting Phase 3 Interventional

High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)

NCT05589181
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
High Dose Buprenorphine, Standard Buprenorphine Dose
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep

NCT05458609
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Lemborexant 10 mg, Naltrexone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence

NCT00167232
View directory record Official record
Conditions
Cocaine Dependence, Alcoholism
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Acetaminophen IV vs Hydromorphone IV in the ED

NCT03107481
View directory record Official record
Conditions
Pain, Acute
Interventions
Acetaminophen, Hydromorphone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Early Phase 1 Interventional

The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion

NCT00667771
View directory record Official record
Conditions
Alcohol Dependence, Alcoholism
Interventions
Naltrexone
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 6:55 AM EDT
Active, not recruiting Not applicable Interventional

CREST: Capsular Repair During Hip Arthroscopy

NCT03372564
View directory record Official record
Conditions
Hip Arthroscopy
Interventions
Hip Capsule Repair
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
3
States / cities
Scottsdale, Arizona • Westmont, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

NCT00129246
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Naltrexone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 28, 2026, 6:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy

NCT04791761
View directory record Official record
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen, Opioid disposal pouch, Opioid disposal education
Drug · Other
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 28, 2026, 6:55 AM EDT
Terminated Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

NCT01135524
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
89
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairfield, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 1 Interventional

Alternate-Day Buprenorphine. Phase V - 6

NCT00000224
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
30 Years to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 4 Interventional

Buprenorphine and Integrated HIV Care

NCT00317460
View directory record Official record
Conditions
Substance-related Disorders, Drug Addiction, Human Immunodeficiency Virus, AIDS, HIV Infections
Interventions
Physician Management, Counseling
Other · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Not applicable Interventional Results available

Stress, Distress Intolerance, and Drug Dependence

NCT00430482
View directory record Official record
Conditions
Substance Dependence
Interventions
Cognitive Behavioral Therapy, Individual Counseling
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

NCT02537574
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Oceanside, California • Orange, California • Lauderhill, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 28, 2026, 6:55 AM EDT
Withdrawn Phase 2 Interventional

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

NCT04115020
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 4 Interventional

Biomarkers of Injectable Extended Release Naltrexone Treatment

NCT02324725
View directory record Official record
Conditions
Heroin Dependence, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

NCT00853320
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block

NCT03117140
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Ropivacaine 0.75%, Ropivacaine 0.75% + 300 mcg Buprenorphine, Ropivacaine 0.75% + 75 mcg clonidine, Ropivacaine 0.75% + 8 mg dexamethasone
Drug
Lead sponsor
Melinda Seering
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 28, 2026, 6:55 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy

NCT00183950
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Noscapine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 28, 2026, 6:55 AM EDT
Not listed No phase listed Observational

Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing

NCT05307458
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 28, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

NCT01452789
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
sublingual buprenorphine, oral morphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 28, 2026, 6:55 AM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 28, 2026, 6:55 AM EDT